Complete Remission in Patients With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab - A Multicenter, Prospective Observational Cohort Study in Canada, Italy, and Israel
Latest Information Update: 08 Jan 2025
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SUNRISE
- Sponsors Takeda
- 06 Jan 2025 Planned End Date changed from 12 Jan 2025 to 31 Oct 2025.
- 06 Jan 2025 Planned primary completion date changed from 12 Jan 2025 to 31 Oct 2025.
- 14 Jun 2024 Planned End Date changed from 1 Jan 2025 to 12 Jan 2025.